| Long name: |
BARD1 Primary Polyclonal Antibody |
| Also known as: |
BARD1 PAb |
| Category: |
Primary Antibodies |
| Conjugation: |
Unconjugated |
| Target Antigen: |
BARD1 |
| Specificity: |
This is a highly specific antibody against BARD1 |
| Modification(s): |
None |
| Modification site(s): |
Unmodified antibody |
| Clonality: |
Polyclonal antibody |
| Clone number: |
Polyclonal antibody |
| Concentration: |
1ug per 1ul |
| Immunogen range: |
120-170/777 |
| Subcellular location: |
Nucleus |
| Source: |
This antibody was obtained by immunization of the host with KLH conjugated synthetic peptide derived from human BARD1 |
| Gene ID number: |
580 |
| Swiss Prot: |
Q99728 |
| Tested Applications: |
IF(IHC-P), IHC-P, WB |
| Recommended dilutions: |
IF(IHC-P)(1:50-200), IHC-P(1:100-500), WB(1:100-1000) |
| Cross reactivity: |
Mouse, Rat, Human |
| Cross reactive species details: |
not every possible cross-reactivity is known, Due to limited amount of testing and knowledge |
| Background of the target antigen: |
Acts by mediating ubiquitin E3 ligase activity that is required for its tumor suppressor function, Also forms a heterodimer with CSTF1/CSTF-50 to modulate mRNA processing and RNAP II stability by inhibiting pre-mRNA 3' cleavage, Plays a central role in the control of the cell cycle in response to DNA damage, The BRCA1-BARD1 heterodimer specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability, Probable E3 ubiquitin-protein ligase |
| Purification method: |
This antibody was purified via Protein A |
| Storage conditions: |
50% glycerol and 0, Store at -20°, 09% sodium azide, C for up to 1 year, Keep the antibody in aqueous buffered solution containing 1% BSA |
| Synonym names: |
BARD-1, BARD1, BRCA1-associated RING domain protein 1 |
| Properties: |
C, C for long term storage and for short term at + 5°, If you buy Antibodies supplied by Bioss Primary Unconjugated Antibodies they should be stored frozen at - 24° |
| Gene target: |
BARD1 |
| Short name: |
BARD1 Antibody |
| Technique: |
antibodies against human proteins, antibodies for, Antibody |
| Alternative name: |
early onset associated RING domain 1 (Antibody to), breast cancer 1 |
| Alternative technique: |
antibodies |
| Alternative to gene target: |
BARD1 and IDBG-643630 and ENSBTAG00000033690 and 530961, BARD1 and IDBG-80113 and ENSG00000138376 and 580, Bard1 and IDBG-164443 and ENSMUSG00000026196 and 12021, nuclei, protein heterodimerization activity, this GO :0000151 and ubiquitin ligase complex and cellular component this GO :0001894 and tissue homeostasis and biological process this GO :0003723 and RNA binding and molecular function this GO :0004842 and ubiquitin-protein transferase activity and molecular function this GO :0005515 and protein binding and molecular function this GO :0005634 and nucleus and cellular component this GO :0005730 and nucleolus and cellular component this GO :0005737 and cytoplasm and cellular component this GO :0006281 and DNA repair and biological process this GO :0006974 and cellular response to DNA damage stimulus and biological process this GO :0007050 and cell cycle arrest and biological process this GO :0008270 and zinc ion binding and molecular function this GO :0016567 and protein ubiquitination and biological process this GO :0016874 and ligase activity and molecular function this GO :0019900 and kinase binding and molecular function this GO :0031436 and BRCA1-BARD1 complex and cellular component this GO :0031441 and negative regulation of mRNA 3'-end processing and biological process this GO :0042325 and regulation of phosphorylation and biological process this GO :0042803 and protein homodimerization activity and molecular function this GO :0043065 and positive regulation of apoptotic process and biological process this GO :0043066 and negative regulation of apoptotic process and biological process this GO :0043231 and intracellular membrane-bounded organelle and cellular component this GO :0045732 and positive regulation of protein catabolic process and biological process this GO :0046826 and negative regulation of protein export from nucleus and biological process this GO :0046982 and protein heterodimerization activity and molecular function this GO :0070531 and BRCA1-A complex and cellular component this GO :0085020 and protein K6-linked ubiquitination and biological process, this GO :0003723 : RNA binding, this GO :0003723 : RNA binding and also this GO :0004842 : ubiquitin-protein transferase activity and also this GO :0005515 : protein binding and also this GO :0008270 : zinc ion binding and also this GO :0016874 : ligase activity and also this GO :0019900 : kinase binding and also this GO :0042803 : protein homodimerization activity and also this GO :0046982 : protein heterodimerization activity, this GO :0004842 : ubiquitin-protein transferase activity, this GO :0005515 : protein binding, this GO :0008270 : zinc ion binding, this GO :0016874 : ligase activity, this GO :0019900 : kinase binding, this GO :0042803 : protein homodimerization activity, this GO :0046982 : protein heterodimerization activity, BRCA1 associated RING domain 1 |
| Identity: |
952 |
| Gene: |
BARD1 |
More about : BARD1 |
| Long gene name: |
BRCA1 associated RING domain 1 |
| Locus: |
2q35 |
| Discovery year: |
1998-08-05 |
| Entrez gene record: |
580 |
| Pubmed identfication: |
8944023 9425226 15159397 |
| RefSeq identity: |
NM_000465 |
| Classification: |
Ankyrin repeat domain containing BRCA1 B complex |
| Havana BLAST/BLAT: |
OTTHUMG00000133016 |